-
公开(公告)号：US20100279947A1
公开(公告)日：2010-11-04
申请号：US11998194
申请日：2007-11-28
IPC分类号： A61K38/16 , C07K14/005 , C12N15/63 , C12N5/10 , C07K16/08 , C07H21/04 , G01N33/53 , A61P35/00
CPC分类号： C07K14/005 , A61K38/00 , A61K38/162 , A61K48/00 , C07K14/4747 , C07K16/18 , C07K2319/00 , C12N2750/10022 , C12N2750/10043
摘要： Phosphorylated Apoptin is described. Apoptin is tumor-specifically phosphorylated and part of the Apoptin apoptotic pathway in tumor cells is elucidated. New therapeutic possibilities, for example, novel therapeutic compounds that can work alone or, sequentially to, or jointly with other known compounds. Also, the use of tumor-specifically phosphorylation of Apoptin for diagnostic purposes is described. Such a diagnostic purpose can, for example, be a method for detecting the presence of cancer cells or cells that are cancer prone or a method to identify a putative cancer inducing agent or a method for the in vitro treatment effect of Apoptin on tumor cells by testing the phosphorylation state of Apoptin. Even more, the invention provides possibilities to further elucidate the apoptotic pathway and to identify for example crucial mediators of phosphorylation in human tumor cells. Interfering with such a mediator could provide new anti-cancer therapies.
摘要翻译： 描述了磷酸化的Apoptin。 凋亡素是肿瘤特异性磷酸化的，并且阐明肿瘤细胞中部分凋亡途径的凋亡途径。 新的治疗可能性，例如，可以单独或连续地或与其它已知化合物一起工作的新型治疗化合物。 此外，描述了用于诊断目的的使用肿瘤特异性磷酸化的Apoptin。 这样的诊断目的可以是例如用于检测癌细胞或癌症倾向的细胞的存在的方法或者鉴定推定的癌症诱导剂的方法或者通过以下方法检测凋亡素对肿瘤细胞的体外治疗效果的方法 测试Apoptin的磷酸化状态。 更进一步地，本发明提供进一步阐明凋亡途径并鉴定例如人肿瘤细胞中磷酸化的关键介质的可能性。 干扰这种介质可以提供新的抗癌疗法。
-
公开(公告)号：US07319034B2
公开(公告)日：2008-01-15
申请号：US10083849
申请日：2001-10-19
IPC分类号： C12N15/85
CPC分类号： C07K14/005 , A61K38/00 , A61K38/162 , A61K48/00 , C07K14/4747 , C07K16/18 , C07K2319/00 , C12N2750/10022 , C12N2750/10043
摘要： Phosphorylated Apoptin is described. Apoptin is tumor-specifically phosphorylated and part of the Apoptin apoptotic pathway in tumor cells is elucidated. New therapeutic possibilities, for example, novel therapeutic compounds that can work alone or, sequentially to, or jointly with other known compounds. Also, the use of tumor-specifically phosphorylation of Apoptin for diagnostic purposes is described. Such a diagnostic purpose can, for example, be a method for detecting the presence of cancer cells or cells that are cancer prone or a method to identify a putative cancer inducing agent or a method for the in vitro treatment effect of Apoptin on tumor cells by testing the phosphorylation state of Apoptin. Even more, the invention provides possibilities to further elucidate the apoptotic pathway and to identify for example crucial mediators of phosphorylation in human tumor cells. Interfering with such a mediator could provide new anti-cancer therapies.
摘要翻译： 描述了磷酸化的Apoptin。 凋亡素是肿瘤特异性磷酸化的，并且阐明肿瘤细胞中部分凋亡途径的凋亡途径。 新的治疗可能性，例如，可以单独或连续地或与其它已知化合物一起工作的新型治疗化合物。 此外，描述了用于诊断目的的使用肿瘤特异性磷酸化的Apoptin。 这样的诊断目的可以是例如用于检测癌细胞或癌症倾向的细胞的存在的方法或者鉴定推定的癌症诱导剂的方法或者通过以下方法检测凋亡素对肿瘤细胞的体外治疗效果的方法 测试Apoptin的磷酸化状态。 更进一步地，本发明提供进一步阐明凋亡途径并鉴定例如人肿瘤细胞中磷酸化的关键介质的可能性。 干扰这种介质可以提供新的抗癌疗法。
-
公开(公告)号：US07767790B2
公开(公告)日：2010-08-03
申请号：US11818169
申请日：2007-06-12
CPC分类号： C07K16/18 , A61K38/00 , A61K48/00 , C07K14/4747
摘要： The invention relates to the field of apoptosis. The invention provides novel therapeutic possibilities, for example novel combinatorial therapies or novel therapeutic compounds that can work alone, sequentially to, or jointly with apoptin, especially in those cases wherein p53 is (partly) non-functional.
摘要翻译： 本发明涉及细胞凋亡领域。 本发明提供新颖的治疗可能性，例如可以独立地，顺序地或与凋亡素联合工作的新型组合疗法或新型治疗化合物，特别是在p53（部分）非功能性的情况下。
-
4.发明授权Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor 失效基于病毒蛋白VP1，VP2和VP3或其编码的病毒序列的鸡贫血病毒突变体和疫苗和用途
公开(公告)号：US6071520A
公开(公告)日：2000-06-06
申请号：US454121
申请日：1995-11-30
CPC分类号： C07K14/005 , C12N15/86 , G01N33/56983 , A61K38/00 , A61K39/00 , C12N2710/14143 , C12N2750/12022 , C12N2750/12034
摘要： Novel proteins of the Chicken Anemia Virus are described and compositions for preventing or treating infections with that virus (CAV), in particular vaccines less pathogenic than the CAV itself, but yet leading to neutralizing antibodies in the immunized animal. Besides, there are described compositions containing antibodies against parts of the CAV for the control of infections with CAV and anti-idiotype antibodies. The invention also provides antibodies and test kits for the detection of CAV. Recombinant DNA molecules derived from CAV and host cells transfected therewith and vaccines based on these host cells are made possible by this invention. The invention also comprises living virus vaccines in which a piece of DNA is brought into a virus infectious to the host. Besides, the invention provides uses of proteins of CAV in the induction of apoptosis, in particular in tumor cells. It further provides the induction of cell death by means of gene therapy.
摘要翻译： PCT No.PCT / NL94 / 00168 Sec。 371日期：1995年11月30日 102（e）1995年11月30日日期PCT 1994年7月19日PCT公布。 出版物WO95 / 03414 日期1995年2月2日描述了鸡贫血病毒的新蛋白质和用于预防或治疗该病毒感染（CAV）的组合物，特别是比CAV本身致病性更低的疫苗，但仍导致免疫动物中的抗体。 此外，还描述了含有抗CAV部分抗体以控制CAV和抗独特型抗体感染的抗体的组合物。 本发明还提供用于检测CAV的抗体和测试试剂盒。 衍生自CAV的重组DNA分子和转染的宿主细胞以及基于这些宿主细胞的疫苗通过本发明成为可能。 本发明还包括活体病毒疫苗，其中一片DNA被带入感染宿主的病毒。 此外，本发明提供CAV蛋白在诱导凋亡中的用途，特别是在肿瘤细胞中的用途。 它进一步提供通过基因治疗诱导细胞死亡。
-
公开(公告)号：US07317096B1
公开(公告)日：2008-01-08
申请号：US09655109
申请日：2000-09-05
CPC分类号： C07K16/18 , A61K38/00 , A61K48/00 , C07K14/4747
摘要： The invention relates to the field of apoptosis. The invention provides novel therapeutic possibilities, for example novel combinatorial therapies or novel therapeutic compounds that can work alone, sequentially to, or jointly with apoptin, especially in those cases wherein p53 is (partly) non-functional.
摘要翻译： 本发明涉及细胞凋亡领域。 本发明提供新颖的治疗可能性，例如可以独立地，顺序地或与凋亡素联合工作的新型组合疗法或新型治疗化合物，特别是在p53（部分）非功能性的情况下。
-
公开(公告)号：US20090311717A1
公开(公告)日：2009-12-17
申请号：US12484370
申请日：2009-06-15
申请人： Jan De Sonneville , Jan Pieter Abrahams , Mathieu Hubertus Maria Noteborn , Maxim Emile Kuil , Henk Verpoorten
发明人： Jan De Sonneville , Jan Pieter Abrahams , Mathieu Hubertus Maria Noteborn , Maxim Emile Kuil , Henk Verpoorten
CPC分类号： G01N21/05 , B01L3/502715 , B01L7/00 , B01L2200/027 , B01L2200/10 , B01L2300/044 , B01L2300/0829 , B01L2300/123 , B01L2300/163 , B01L2300/168 , B01L2300/1838 , B01L2400/0415 , G01N2021/0346
摘要： The invention provides a microfluidic device wherein capillaries are connected to the microfluidic device by a deformable penetrable substance.
摘要翻译： 本发明提供一种微流体装置，其中毛细管通过可变形的可穿透物质连接到微流体装置。
-
7.发明授权Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor 失效基于病毒蛋白VP1，VP2和VP3或其编码的病毒序列的鸡贫血病毒突变体和疫苗和用途公开(公告)号：US07427658B2
公开(公告)日：2008-09-23
申请号：US09740676
申请日：2000-12-18
IPC分类号： C07K7/08 , C07K14/01 , C07K16/46 , C07K19/00 , C12N15/62 , C12N1/21 , C12N5/10 , C12N15/34 , A61K39/12 , A61K39/395
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N15/86 , C12N2750/10022 , C12N2750/14143 , C12N2830/00 , C12N2830/60 , G01N33/56983
摘要： The coding information for three putative chicken anemia virus proteins (VP1, VP2, VP3) was inserted into a baculovirus vector and expressed in insect cells. Only lysates of insect cells which have synthesized equivalent amounts of all three recombinant CAV proteins or cells which synthesized mainly VP1 plus VP2 induced neutralizing antibodies directed against CAV in inoculated chickens. Progeny of those chickens were protected against clinical disease after CAV challenge. Inoculation of a mixture of lysates of cells that were separately infected with VP1-, VP2- and VP3-recombinant baculovirus did not induce significant levels of neutralizing antibody directed against CAV and their progeny were not protected against CAV challenge. Expression in the same cell of at least VP1 plus VP2 is required to obtain sufficient protection in chickens. Therefore, recombinant CAV proteins produced by baculovirus vectors can be used as a sub-unit vaccine against CAV infections.
摘要翻译： 将三种推定的鸡贫血病毒蛋白（VP1，VP2，VP3）的编码信息插入杆状病毒载体中，并在昆虫细胞中表达。 只有合成了相当量的所有三种重组CAV蛋白或主要合成VP1加VP2的细胞的昆虫细胞裂解液才能诱导接种鸡中抗CAV的中和抗体。 在CAV攻击后，这些鸡的后代受到临床疾病的保护。 分别感染VP1，VP2和VP3-重组杆状病毒的细胞裂解液的混合物接种不诱导针对CAV的显着水平的中和抗体，并且其后代不受CAV攻击的保护。 在至少VP1加VP2的相同细胞中的表达需要在鸡中获得足够的保护。 因此，由杆状病毒载体产生的重组CAV蛋白可用作针对CAV感染的亚单位疫苗。
-
8.发明授权Methods and means for inducing apoptosis by interfering with Bip-like proteins 失效通过干扰Bip样蛋白诱导凋亡的方法和手段公开(公告)号：US06472142B1
公开(公告)日：2002-10-29
申请号：US09581001
申请日：2000-07-24
IPC分类号： C12Q100
CPC分类号： C07K14/4747 , A61K38/00
摘要： The invention relates to activation of apoptosis by means of interference of the function of Bip-like compounds. Also the invention relates to anti-tumor therapies with compounds, which negatively interfere with Bip-like compounds leading to induction of apoptosis, resulting in the elimination of tumor cells. Also the invention relates to therapies for diseases related to aberrant apoptosis induction, such as auto-immune diseases. Also the invention describes the diagnosis of cells, which are susceptible to apoptin or apoptin-like induced apoptosis.
摘要翻译： 本发明涉及通过干扰Bip样化合物的功能来激活凋亡。 本发明还涉及具有化合物的抗肿瘤治疗，其负面地干扰导致凋亡诱导的Bip样化合物，导致肿瘤细胞的消除。 本发明还涉及与异常凋亡诱导相关的疾病的疗法，例如自身免疫疾病。 本发明还描述了细胞的诊断，其易于凋亡或凋亡样诱导的细胞凋亡。
-
9.发明授权Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1 VP2 and VP3 or sequences of that virus coding therefor 失效鸡贫血病毒突变体和基于病毒蛋白VP1 VP2和VP3或其编码的病毒序列的疫苗和用途公开(公告)号：US06217870B1
公开(公告)日：2001-04-17
申请号：US09057963
申请日：1998-04-09
IPC分类号： A61K3900
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N15/86 , C12N2710/14143 , C12N2750/10022 , C12N2750/10034 , C12N2830/00 , C12N2830/60 , G01N33/56983
摘要： The coding information for three putative chicken anemia virus proteins (VP1, VP2, VP3) was inserted into a baculovirus vector and expressed in insect cells. The immunogenic properties of the chicken anemia virus (CAV) proteins produced separately or together in insect-cell cultures were analyzed by inoculating them into chickens. Only lysates of insect cells which have synthesized equivalent amounts of all three recombinant CAV proteins or cells which synthesized mainly VP1 plus VP2 induced neutralizing antibodies directed against CAV in inoculated chickens. Progeny of those chickens were protected against clinical disease after CAV challenge. Inoculation of a mixture of lysates of cells that were separately infected with VP1-, VP2- and VP3-recombinant baculovirus did not induce significant levels of neutralizing antibody directed against CAV and their progeny were not protected against CAV challenge. Our results indicate that expression in the same cell of at least two CAV proteins, VP1 plus VP2, is required to obtain sufficient protection in chickens. Therefore, recombinant CAV proteins produced by baculovirus vectors can be used as a sub-unit vaccine against CAV infections.
摘要翻译： 将三种推定的鸡贫血病毒蛋白（VP1，VP2，VP3）的编码信息插入杆状病毒载体中，并在昆虫细胞中表达。 通过将它们接种到鸡中来分析在昆虫细胞培养物中单独或一起产生的鸡贫血病毒（CAV）蛋白的免疫原性。 只有合成了相当量的所有三种重组CAV蛋白或主要合成VP1加VP2的细胞的昆虫细胞裂解液才能诱导接种鸡中抗CAV的中和抗体。 在CAV攻击后，这些鸡的后代受到临床疾病的保护。 分别感染VP1，VP2和VP3-重组杆状病毒的细胞裂解液的混合物接种不诱导针对CAV的显着水平的中和抗体，并且其后代不受CAV攻击的保护。 我们的研究结果表明，需要在至少两种CAV蛋白VP1加VP2的相同细胞中表达以获得足够的鸡保护。 因此，由杆状病毒载体产生的重组CAV蛋白可用作针对CAV感染的亚单位疫苗。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.025 秒)
